CNSX:CURA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Curaleaf Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CURA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.9%

CURA

-1.6%

CA Pharmaceuticals

-1.2%

CA Market


1 Year Return

66.1%

CURA

-16.5%

CA Pharmaceuticals

-5.5%

CA Market

Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned -16.5% over the past year.

Return vs Market: CURA exceeded the Canadian Market which returned -5.5% over the past year.


Shareholder returns

CURAIndustryMarket
7 Day-4.9%-1.6%-1.2%
30 Day25.9%18.9%0.4%
90 Day9.6%3.1%-0.3%
1 Year66.1%66.1%-16.5%-16.5%-2.1%-5.5%
3 Yearn/a-21.5%-22.2%3.9%-6.2%
5 Yearn/a201.0%199.4%32.3%12.0%

Price Volatility Vs. Market

How volatile is Curaleaf Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Curaleaf Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CURA (CA$11.96) is trading below our estimate of fair value (CA$30.02)

Significantly Below Fair Value: CURA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CURA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: CURA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CURA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CURA is overvalued based on its PB Ratio (7.1x) compared to the CA Pharmaceuticals industry average (1.4x).


Next Steps

Future Growth

How is Curaleaf Holdings forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

58.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CURA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: CURA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CURA's is expected to become profitable in the next 3 years.

Revenue vs Market: CURA's revenue (31.5% per year) is forecast to grow faster than the Canadian market (5.8% per year).

High Growth Revenue: CURA's revenue (31.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CURA's Return on Equity is forecast to be low in 3 years time (3%).


Next Steps

Past Performance

How has Curaleaf Holdings performed over the past 5 years?

-58.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CURA is currently unprofitable.

Growing Profit Margin: CURA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 58.7% per year.

Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).


Return on Equity

High ROE: CURA has a negative Return on Equity (-7.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Curaleaf Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: CURA's short term assets ($340.1M) exceed its short term liabilities ($129.5M).

Long Term Liabilities: CURA's short term assets ($340.1M) do not cover its long term liabilities ($525.4M).


Debt to Equity History and Analysis

Debt Level: CURA's debt to equity ratio (41.3%) is considered high.

Reducing Debt: Insufficient data to determine if CURA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CURA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CURA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CURA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Joseph Lusardi (46 yo)

4.58yrs

Tenure

US$2,231,000

Compensation

Mr. Joseph F. Lusardi serves as a Director of Curaleaf Holdings, Inc. since March 2016 and was its President until January 2019. Mr. Lusardi has been the Chief Executive Officer of Curaleaf Holdings, Inc. ...


CEO Compensation Analysis

Compensation vs Market: Joseph's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD3.97M).

Compensation vs Earnings: Joseph's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Boris Jordan
Executive Chairmanno dataUS$1.50m19.78%
$ 1.7b
Joseph Lusardi
CEO & Director4.58yrsUS$2.23m0.64%
$ 53.4m
Joseph Bayern
President0.83yrno datano data
Michael Carlotti
Chief Financial Officer0.75yrno datano data
Neil Davidson
COO & Treasurer0.67yrno data0.031%
$ 2.6m
Daniel Foley
Vice President of Finance & Investor Relationsno datano datano data
Peter Clateman
Executive VP of Business Development & Interim General Counsel0.75yrno data0.025%
$ 2.1m
James Shorris
Chief Compliance Officer0.58yrno datano data
Tracy Brady
Vice President of Corporate Communications0.83yrno datano data
Mark Russ
Senior Vice President of Salesno datano datano data
Jason White
Chief Marketing Officer0.67yrno datano data
Carolyn Fedigan
Senior Vice President of Human Resourcesno datano data0.0086%
$ 716.9k

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: CURA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Boris Jordan
Executive Chairmanno dataUS$1.50m19.78%
$ 1.7b
Joseph Lusardi
CEO & Director4.58yrsUS$2.23m0.64%
$ 53.4m
Mitchell Kahn
Director0.25yrno data0.86%
$ 71.7m
Peter Derby
Independent Director2yrsUS$12.50k0.066%
$ 5.6m
Karl Johansson
Independent Director2yrsUS$12.50k0.0026%
$ 218.8k
Steven Patierno
Chairman of the Medical Advisory Boardno dataUS$81.95kno data
David Casarett
Member of the Medical Advisory Boardno datano datano data
Robert Schnoll
Member of the Medical Advisory Boardno datano datano data
Jaswinder Grover
Independent Director0.67yrno data0.83%
$ 69.5m

2.0yrs

Average Tenure

59yo

Average Age

Experienced Board: CURA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CURA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.4%.


Top Shareholders

Company Information

Curaleaf Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Curaleaf Holdings, Inc.
  • Ticker: CURA
  • Exchange: CNSX
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$8.384b
  • Shares outstanding: 657.60m
  • Website: https://www.curaleaf.com

Number of Employees


Location

  • Curaleaf Holdings, Inc.
  • 301 Edgewater Place
  • Suite 405
  • Wakefield
  • Massachusetts
  • 1880
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CURACNSX (Canadian National Stock Exchange)YesSubordinated Voting SharesCACADOct 2018
CURL.FOTCPK (Pink Sheets LLC)YesSubordinated Voting SharesUSUSDOct 2018

Biography

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Ope ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:51
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.